Effect of bubble-bubble interaction in Cu−Al2O3/H2O hybrid nanofluids during multibubble growth process

Por Ahmed K. Abu-Nab, Ali F. Abu-Bakr
Publicado em 2022-05-01

Accelerating functional MRI using fixed‐rank approximations and radial‐cartesian sampling

Por Chiew, Mark, Graedel, Nadine N., McNab, Jennifer A., Smith, Stephen M., Miller, Karla L.
Publicado no Magn Reson Med (2016)

Standards for the measurement of birth weight, length and head circumference at term in neonates of European, Chinese and South Asian ancestry

Por Janssen, Patricia A, Thiessen, Paul, Klein, Michael C, Whitfield, Michael F, MacNab, Ying C, Cullis-Kuhl, Sue C
Publicado em 2007

Suitability of bovine portion condemnations at provincially-inspected abattoirs in Ontario Canada for food animal syndromic surveillance

Por Alton Gillian D, Pearl David L, Bateman Ken G, McNab W Bruce, Berke Olaf
Publicado em 2012-06-01

Suitability of bovine portion condemnations at provincially-inspected abattoirs in Ontario Canada for food animal syndromic surveillance

Por Alton, Gillian D, Pearl, David L, Bateman, Ken G, McNab, W Bruce, Berke, Olaf
Publicado em 2012

Is there a role of nab-paclitaxel in the treatment of advanced non-small cell lung cancer? The data suggest yes

Por Villaruz, Liza C., Socinski, Mark A.
Publicado no Eur J Cancer (2016)

Stromal disrupting effects of nab-paclitaxel in pancreatic cancer

Por Alvarez, R, Musteanu, M, Garcia-Garcia, E, Lopez-Casas, P P, Megias, D, Guerra, C, Muñoz, M, Quijano, Y, Cubillo, A, Rodriguez-Pascual, J, Plaza, C, de Vicente, E, Prados, S, Tabernero, S, Barbacid, M, Lopez-Rios, F, Hidalgo, M
Publicado em 2013

Update on taxanes in the first-line treatment of advanced non-small-cell lung cancer

Por Socinski, M.A.
Publicado em 2014

The dual PI3K/mTOR inhibitor NVP-BEZ235 enhances nab-paclitaxel antitumor response in experimental gastric cancer

Por ZHANG, CHANG-HUA, AWASTHI, NIRANJAN, SCHWARZ, MARGARET A., SCHWARZ, RODERICH E.
Publicado em 2013

SPARC independent drug delivery and antitumour effects of nab-paclitaxel in genetically engineered mice

Por Neesse, Albrecht, Frese, Kristopher K, Chan, Derek S, Bapiro, Tashinga E, Howat, William J, Richards, Frances M, Ellenrieder, Volker, Jodrell, Duncan I, Tuveson, David A
Publicado em 2014

nab-Paclitaxel–Based Therapy in Underserved Patient Populations: The ABOUND.PS2 Study in Patients With NSCLC and a Performance Status of 2

Por Ajeet Gajra, Nagla Abdel Karim, Deborah A. Mulford, Liza Cosca Villaruz, Marc Ryan Matrana, Haythem Y. Ali, Edgardo S. Santos, Tymara Berry, Teng Jin Ong, Alexandra Sanford, Katayoun Amiri, David R. Spigel
Publicado em 2018-07-01

SWOG S0800 (NCI CDR0000636131): addition of bevacizumab to neoadjuvant nab-paclitaxel with dose...

Por Nahleh, Z. A., Barlow, W. E., Hayes, D. F., Schott, A. F., Gralow, J. R., Sikov, W. M., Perez, E. A., Chennuru, S., Mirshahidi, H. R., Corso, S. W., Lew, D. L., Pusztai, L., Livingston, R. B., Hortobagyi, G. N.
Publicado no Breast Cancer Res Treat (2016)

Paclitaxel injection concentrate for nanodispersion versus nab-paclitaxel in women with metastatic breast cancer: a multicenter, randomized, comparative phase II/III study

Por Jain, Minish M., Gupte, Smita U., Patil, Shekhar G., Pathak, Anand B., Deshmukh, Chetan D., Bhatt, Niraj, Haritha, Chiramana, Govind Babu, K., Bondarde, Shailesh A., Digumarti, Raghunadharao, Bajpai, Jyoti, Kumar, Ravi, Bakshi, Ashish V., Bhattacharya, Gouri Sankar, Patil, Poonam, Subramanian, Sundaram, Vaid, Ashok K., Desai, Chirag J., Khopade, Ajay, Chimote, Geetanjali, Bapsy, Poonamalle P., Bhowmik, Shravanti
Publicado no Breast Cancer Res Treat (2016)

Comparative Effectiveness of Gemcitabine plus Nab-Paclitaxel and FOLFIRINOX in the First-Line...

Por Sara Pusceddu, Michele Ghidini, Martina Torchio, Francesca Corti, Gianluca Tomasello, Monica Niger, Natalie Prinzi, Federico Nichetti, Andrea Coinu, Maria Di Bartolomeo, Mary Cabiddu, Rodolfo Passalacqua, Filippo de Braud, Fausto Petrelli
Publicado em 2019-04-01

Comparative effectiveness and safety of nab-paclitaxel plus carboplatin vs gemcitabine plus...

Por Mudad, Raja, Patel, Manish B, Margunato-Debay, Sandra, Garofalo, David, Lal, Lincy S
Publicado no Lung Cancer (Auckl) (2017)

nab-Paclitaxel-Based Therapy in Underserved Patient Populations: The ABOUND.70+ Study in Elderly Patients With Advanced NSCLC

Por Langer, Corey J., Kim, Edward S., Anderson, Eric C., Jotte, Robert M., Modiano, Manuel, Haggstrom, Daniel E., Socoteanu, Matei P., Smith, David A., Dakhil, Christopher, Konduri, Kartik, Berry, Tymara, Ong, Teng J., Sanford, Alexandra, Amiri, Katayoun, Goldman, Jonathan W., Weiss, Jared
Publicado no Front Oncol (2018)

Comparative effectiveness of early-line nab-paclitaxel vs. paclitaxel in patients with metastatic breast cancer: a US community-based real-world analysis

Por Mahtani, Reshma L, Parisi, Monika, Glück, Stefan, Ni, Quanhong, Park, Siyeon, Pelletier, Corey, Faria, Claudio, Braiteh, Fadi
Publicado no Cancer Manag Res (2018)

nab-Paclitaxel–Based Therapy in Underserved Patient Populations: The ABOUND.PS2 Study in Patients With NSCLC and a Performance Status of 2

Por Gajra, Ajeet, Karim, Nagla Abdel, Mulford, Deborah A., Villaruz, Liza Cosca, Matrana, Marc Ryan, Ali, Haythem Y., Santos, Edgardo S., Berry, Tymara, Ong, Teng Jin, Sanford, Alexandra, Amiri, Katayoun, Spigel, David R.
Publicado no Front Oncol (2018)

A randomized placebo-controlled clinical study of nab-paclitaxel as second-line chemotherapy for patients with advanced non-small cell lung cancer in China

Por Wu, Yueming, Feng, Jiang, Hu, Weiwei, Luo, Qingquan
Publicado no Biosci Rep (2017)

Nab-Paclitaxel in combination with Cisplatin Versus Docetaxel Plus Cisplatin as First-Line Therapy in Non-small Cell Lung Cancer

Por Chen, Yi, Li, Jinyu, Chen, Shixue, Zhang, Yibao, Hu, Yi, Zhang, Guoqing, Yan, Xiang, Jiao, Shunchang
Publicado no Sci Rep (2017)